G P T Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.50 Cr
as on 16-12-2024
- Paid Up Capital ₹ 7.33 Cr
as on 16-12-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.62 Cr
as on 16-12-2024
- Revenue -11.46%
(FY 2022)
- Profit 24.50%
(FY 2022)
- Ebitda 21.26%
(FY 2022)
- Net Worth -72.94%
(FY 2022)
- Total Assets 2.75%
(FY 2022)
About G P T Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 7.33 Cr.
The company currently has active open charges totaling ₹5.62 Cr.
Ashok Adityan, Badari Raghunath, and Animesh Shah serve as directors at the Company.
- CIN/LLPIN
U24233TG2009PTC064156
- Company No.
064156
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does G P T Pharmaceuticals Private Limited offer?
G P T Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Pharmaceutical Excipients.
Who are the key members and board of directors at G P T Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Adityan  | Director | 26-Jun-2009 | Current |
| Badari Raghunath | Director | 10-Apr-2015 | Current |
| Animesh Shah | Director | 19-Feb-2024 | Current |
Financial Performance and Corporate Structure Insights of G P T Pharmaceuticals.
G P T Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 11.46% decrease. The company also saw a substantial improvement in profitability, with a 24.5% increase in profit. The company's net worth observed a substantial decline by a decrease of 72.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of G P T Pharmaceuticals?
In 2021, G P T Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 02 May 2019 | ₹4.17 Cr | Open |
State Bank Of India Creation Date: 25 Nov 2010 | ₹1.45 Cr | Open |
How Many Employees Work at G P T Pharmaceuticals?
G P T Pharmaceuticals has a workforce of 46 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of G P T Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped G P T Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
